Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

NEXT STORY
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
PREV STORY
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

author_avatar
NASDAQ Market News

Global Smartwatch Market Report 2021-2026: Market is Expected to Grow at the Rate of 19.5% CAGR

author_avatar
NASDAQ Market News

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is projected to reach US$56,737.2 Million in 2031: Visiongain Research Inc

author_avatar
NASDAQ Market News